165 related articles for article (PubMed ID: 32277842)
1. Sustained Carbohydrate Antigen 19-9 Response to Neoadjuvant Chemotherapy in Borderline Resectable Pancreatic Cancer Predicts Progression and Survival.
Rose JB; Edwards AM; Rocha FG; Clark C; Alseidi AA; Biehl TR; Lin BS; Picozzi VJ; Helton WS
Oncologist; 2020 Oct; 25(10):859-866. PubMed ID: 32277842
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
Doppenberg D; van Dam JL; Han Y; Bonsing BA; Busch OR; Festen S; van der Harst E; de Hingh IH; Homs MYV; Kwon W; Lee M; Lips DJ; de Meijer VE; Molenaar IQ; Nuyttens JJ; Patijn GA; van Roessel S; van der Schelling GP; Suker M; Versteijne E; de Vos-Geelen J; Wilmink JW; van Eijck CHJ; van Tienhoven G; Jang JY; Besselink MG; Groot Koerkamp B;
Br J Surg; 2023 Sep; 110(10):1374-1380. PubMed ID: 37440421
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
Okada K; Murakami Y; Uemura K; Kondo N; Nakagawa N; Seo S; Otsuka H; Takahashi S
Langenbecks Arch Surg; 2020 Aug; 405(5):623-633. PubMed ID: 32592044
[TBL] [Abstract][Full Text] [Related]
4. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
Ono Y; Inoue Y; Ito H; Sasaki T; Takeda T; Ozaka M; Sasahira N; Hiratsuka M; Matsueda K; Oba A; Sato T; Saiura A; Takahashi Y
HPB (Oxford); 2023 Jan; 25(1):100-108. PubMed ID: 36280425
[TBL] [Abstract][Full Text] [Related]
5. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
6. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy.
Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J
J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644
[TBL] [Abstract][Full Text] [Related]
8. Vasculitis, CA19-9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma.
Piper M; Ross RB; Hu J; Watanabe S; Knitz M; Mehrotra S; Shulick R; Chiaro MD; Karam SD
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):627-639. PubMed ID: 36599398
[TBL] [Abstract][Full Text] [Related]
9. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
10. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity.
Thalji SZ; Aldakkak M; Christians KK; Clarke CN; George B; Kamgar M; Erickson BA; Hall WA; Chisholm P; Kulkarni N; Doucette S; Evans DB; Tsai S
J Surg Oncol; 2023 Jul; 128(1):41-50. PubMed ID: 36960919
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
13. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer.
Liu H; D'Alesio M; AlMasri S; Hammad A; Desilva A; Lebowitz S; Rieser C; Ashwat E; Hampton E; Khachfe H; Laffey M; Singhi A; Bahary N; Lee K; Zureikat A; Paniccia A
HPB (Oxford); 2023 May; 25(5):521-532. PubMed ID: 36804826
[TBL] [Abstract][Full Text] [Related]
14. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
15. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.
Kim HS; Lee M; Han Y; Kang JS; Kang YH; Sohn HJ; Kwon W; Lee DH; Jang JY
J Hepatobiliary Pancreat Sci; 2023 Jul; 30(7):924-934. PubMed ID: 36652346
[TBL] [Abstract][Full Text] [Related]
16. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
17. Predictive factors of survival in patients with borderline resectable pancreatic cancer who received neoadjuvant therapy.
Tezuka K; Okamura Y; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Todaka A; Fukutomi A; Uesaka K
Pancreatology; 2021 Dec; 21(8):1451-1459. PubMed ID: 34462214
[TBL] [Abstract][Full Text] [Related]
18. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
19. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.
Al Abbas AI; Zenati M; Reiser CJ; Hamad A; Jung JP; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2020 Jun; 27(6):2007-2014. PubMed ID: 31898105
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
Miyahara S; Takahashi H; Akita H; Sasaki K; Mukai Y; Iwagami Y; Hasegawa S; Yamada D; Tomimaru Y; Noda T; Wada H; Kobayashi S; Doki Y; Eguchi H
Ann Surg Oncol; 2024 May; 31(5):2932-2942. PubMed ID: 38368291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
